Ptc Therapeutics (PTCT) EBITDA Margin (2012 - 2026)
Ptc Therapeutics' (PTCT) quarterly EBITDA Margin came in at 16.5% in Q1 2026, down 6600.0% year-on-year from 0.25% in Q1 2025, and up 138.07% quarter-over-quarter from 43.33% in Q4 2025.
Ptc Therapeutics (PTCT) EBITDA Margin (2012 - 2026) Analysis & Trends
Ptc Therapeutics' EBITDA Margin history runs 15 years deep, the most recent figure standing at 16.5% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 6600.0% year-over-year to 16.5% in Q1 2026; TTM through Mar 2026 was 7.05%, a 5201.0% decrease from a year earlier, with the FY2025 full-year figure at 50.09%, up 8760.0% from the prior year.
- EBITDA Margin rose to 16.5% in Q1 2026 per PTCT's latest filing, from 43.33% in the prior quarter.
- Across five years, EBITDA Margin topped out at 82.5% in Q1 2025 and bottomed at 119.67% in Q4 2022.
- The 5-year median for EBITDA Margin is 37.37% (2022), against an average of 35.16%.
- Across the five-year window, EBITDA Margin soared 12156 bps in 2023 and sank 7807 bps in 2024, its largest moves.
- Year by year, EBITDA Margin stood at 119.67% in 2022, then surged by 102 bps to 1.9% in 2023, then slumped by 4119 bps to 76.18% in 2024, then surged by 43 bps to 43.33% in 2025, then soared by 138 bps to 16.5% in 2026.
- Per Business Quant, the three latest PTCT EBITDA Margin figures stand at 16.5% (Q1 2026), 43.33% (Q4 2025), and 1.43% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Ptc Therapeutics | 6.34 Bn | 4.45 Bn | 244.52 Mn | 16.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.50% |
| Dec 31, 2025 | -43.33% |
| Sep 30, 2025 | 1.43% |
| Jun 30, 2025 | -19.54% |
| Mar 31, 2025 | 82.50% |
| Dec 31, 2024 | -76.18% |
| Sep 30, 2024 | -27.70% |
| Mar 31, 2024 | -21.63% |
| Dec 31, 2023 | 1.90% |
| Sep 30, 2023 | -60.11% |
| Jun 30, 2023 | -98.01% |
| Mar 31, 2023 | -53.37% |
| Dec 31, 2022 | -119.67% |
| Sep 30, 2022 | -31.40% |
| Jun 30, 2022 | -55.80% |
| Mar 31, 2022 | -58.17% |
| Dec 31, 2021 | -51.28% |
| Sep 30, 2021 | -67.09% |
| Jun 30, 2021 | -84.42% |
| Mar 31, 2021 | -83.22% |